4th Quarter - Amendment

ALEXION PHARMACEUTICALS, INC. for ALEXION PHARMACEUTICALS, INC.

Firm
Client
Income
—
Expenses
$285,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 19, 2015 $285,000 Replaced
4th Quarter - Amendment (this page) Feb 9, 2015 $285,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Trade Promotion Authority TPP TTIP

LobbyistCovered position, as disclosed
GREGORY KALBAUGH New International Trade Counsel, Senate Finance Committee, Repub

Contacted: HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR)

Taxation/Internal Revenue Code TAX

Corporate Tax Reform Proposals EXPIRE Act

LobbyistCovered position, as disclosed
VANESSA PROCTER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR)

Copyright/Patent/Trademark CPT

Patent Transparency and Improvements Act, S. 1720 Patent Abuse Reduction Act, S. 1013

LobbyistCovered position, as disclosed
VANESSA PROCTER —

Contacted: U.S. Trade Representative (USTR); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1720 (113th), S. 1013 (113th)

Health Issues HCR

21st Century Cures Initiative Biosimilars (BPCIA/ACA) Implementation

LobbyistCovered position, as disclosed
VANESSA PROCTER —
HEIDI L WAGNER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.